biostudies-literatureDemetri GDNCI NIH HHS786-93https://www.ebi.ac.uk/biostudies/studies/S-EPMC5070559biostudies-literatureUnknown34(8)<h4>Purpose</h4>This multicenter study, to our knowledge, is the first phase III trial to compare trabectedin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior therapy with an anthracycline and at least one additional systemic regimen.<h4>Patients and methods</h4>Patients were randomly assigned in a 2:1 ratio to receive trabectedin or dacarbazine intravenously every 3 weeks. The primary end point was overall survival (OS), secondary end points were disease control-progression-free survival (PFS), time to progression, objective response rate, and duration of response-as well as safety and patient-reported symptom scoring.<h4>Results</h4>A total of 518 patients were enrolled and randomly assigned to either trabectedin (n = 345) or dacarbazine (n = 173). IJournal of clinical oncology : official journal of the American Society of Clinical OncologyEfficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.PMC5070559P30 CA008748P30 CA086862P30 CA006927Jones RLKnoblauch REvon Mehren MHensley MLDean AParekh TVDemetri GDStaddon AGanjoo KMilhem MPark YCSchuetze SMTawbi HPatel SRMaki RGElias AVan Tine BASpira AKhokhar NZfalseEfficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.<h4>Purpose</h4>This multicenter study, to our knowledge, is the first phase III trial to compare trabectedin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior therapy with an anthracycline and at least one additional systemic regimen.<h4>Patients and methods</h4>Patients were randomly assigned in a 2:1 ratio to receive trabectedin or dacarbazine intravenously every 3 weeks. The primary end point was overall survival (OS), secondary end points were disease control-progression-free survival (PFS), time to progression, objective response rate, and duration of response-as well as safety and patient-reported symptom scoring.<h4>Results</h4>A total of 518 patients were enrolled and randomly assigned to either trabectedin (n = 345) or dacarbazine (n = 173). I2016-01-01T00:00:00Z2016 Mar2026-04-29T09:06:28.207Z2019-03-27T02:27:06ZS-EPMC50705592637114310.1200/JCO.2015.62.473410.1200/jco.2015.62.4734